The Welsh Government today announced that a deal has been agreed in principle for people with cystic fibrosis (CF) living in Wales who stand to benefit from life-saving drugs Orkambi and Symkevi, meaning that everyone in the UK will have access to the most advanced licensed therapies.
NHS Wales follows Scotland and England to provide transformational treatment to two-to-five-year-olds that can dramatically slow the progression of cystic fibrosis (CF).
People in Wales living with cystic fibrosis (CF) who have an R117H mutation will now have access to Kalydeco (ivacaftor) following meetings between the Cystic Fibrosis Trust and the All Wales Medicines Strategy Group.
The Welsh Government has agreed a deal with Vertex Pharmaceuticals to give access to the triple combination therapy, Kaftrio, to people with cystic fibrosis (CF) living in Wales on the day the drug receives its European licence.
Cystic fibrosis community in Wales still waiting for access to ivacaftor (Kalydeco®) despite Welsh Government’s agreement to provide the life-changing drug.
A group of singers living with cystic fibrosis (CF) have brought their voices together for a new charity album ‘Stand Together’ along with 11 other choirs ‘with purpose’.
